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Abstract
Rheumatoid arthritis (RA) is a widespread, debilitating autoimmune disease characterized by
painful inflammation of the joints. Current treatments for RA are either ineffective, expensive, or
have undesirable effects, such as an adverse immune response. To mitigate these effects, we
have designed an exosome-based treatment for inflammation. We chose to utilize exosomes for
their longer half-life in the body, better penetrative capacity, and biocompatibility, thus
improving upon previous RA treatments. To do this, we created a stable cell line to produce
exosomes modified at the surface to express a tumor necrosis factor receptor (TNFR), which
possesses the ability to act as a decoy and soak up soluble tumor necrosis factor alpha (TNFα), a
notable cytokine responsible for inducing inflammation. Exosomes were then harvested from this
cell line and characterized with various imaging techniques to confirm that our desired
modifications had been made. Then we tested the efficacy of our experiment in two models:
direct treatment and coculture. Both models showed decreased levels of inflammation with the
addition of our modified, treatment exosomes. If proven to be clinically successful, this therapy
has the potential to be the first ever exosome decoy treatment.
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1. Introduction
1.1 Background and Motivation
Over 1.3 million people suffer from rheumatoid arthritis (RA) in the United States. RA is a
chronic autoimmune disease of unknown origin, the hallmark symptom of which is swollen,
painful joints.1 Eventually, this condition can result in the irreversible destruction of joints.
Unfortunately, current treatments for RA are limited and have numerous drawbacks. The most
effective treatments for RA are protein-based biologics that prevent inflammation-causing
cytokines from binding to cells, however, use of these drugs can result in suppression of the
immune system, leading to serious and sometimes fatal infections. For this reason, we aimed to
develop and test an anti-inflammatory therapy for RA that utilizes biocompatible nanoparticles
called exosomes.

1.2 Literature Review
1.2.1 Rheumatoid Arthritis
As a progressive autoimmune disease, RA results in chronic joint pain and stiffness that
drastically reduces the quality of life in the people it affects. Typically, the disease manifests
itself through severe discomfort in the hands and wrists, though it may also affect other regions
of the body.2 The underlying pathophysiology behind RA is the body’s immune system attacking
the joints, which leads to thickening of the synovium embedded in the joint capsule. In the
disease mechanism, macrophages of the immune system secrete inflammatory cytokines:
Interleukin-1 (IL-1), Interleukin-6 (IL-6) , and Tumor Necrosis Factor α (TNFα).3 Together,
these cytokines stimulate fibroblast-like synoviocytes to proliferate uncontrollably, in part by the
phenotypic suppression of contact inhibition. These fibroblast-like synoviocytes attract other

1

S. Cohen and P. Emery, “The American College of Rheumatology/European League Against Rheumatism Criteria
for the Classification of Rheumatoid Arthritis: A Game Changer,” Arthritis & Rheumatism 62 no. 9 (2010): 25922594, doi:10.1002/art.27583.
2
“NIAMS Health Information on Rheumatoid Arthritis,” National Institute of Arthritis and Musculoskeletal and
Skin Disease, March, 21, 2018, Accessed June 10, 2018, https://www.niams.nih.gov/health-topics/rheumatoidarthritis.
3
Ankur Shah, Harrison's Principle of Internal Medicine, 18th ed., United States: McGraw Hill, 2738.
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immune cells to the area, creating a chain of deleterious positive feedback that results in
osteoclast and protease activation.4 This contributes to the degradation of both protective
cartilage and bone, as observed in RA pathology.
1.2.2 TNFα and the Inflammation Pathway
As indicated above, pro-inflammatory cytokines IL-1, IL-6, and TNFα represent major players in
the RA transduction cascade. Of these cytokines, TNFα responds the most rapidly, only a few
hours after stimulation, and is found in high concentrations in the synovial fluid of affected
patients.5 Further, research conducted on the interplay between these cytokines has illuminated
the desirability of selective TNFα inhibition, which is sufficient in mitigating the downstream
effects of IL-1 and IL-6, and thus reducing the inflammation response in RA.6 At the cellular
level, inflammation is mediated through the NFkB pathway. When TNFα binds to the TNF
receptor on the exterior cell membrane, the receptor stimulates an enzyme that activates NFkB, a
transcription factor consisting of p65 and p50. Translocation of NFkB to the nucleus allows it to
bind upstream of quintessential inflammation response elements, promoting transcription and
upregulation of inflammation inducing cascades.7 Section 1.2.4 explains how we took advantage
of this pathway to quantify inflammation in a cell culture model.
1.2.3 Exosomes and their Therapeutic Potential
Exosomes are naturally secreted nanovesicles roughly 30-100 nm in size originating from the
intraluminal budding of multivesicular endosomes (MVEs).8 Once thought to be a system of
cellular waste elimination, exosomes have recently been characterized as a model for cell-cell
communication, revitalizing interest in their drug delivery capacity.9 Unlike liposomes and other
synthetic nanoparticle vehicles, exosomes contain transmembrane and membrane-bound proteins

4

Shah, 2738.
M. Feldmann et al, “Definition of TNFα as a Therapeutic Target for Rheumatoid Arthritis,” TNF-Inhibition in the
Treatment of Rheumatoid Arthritis, 2004, 1-22, doi: 10.3109/9780203624388.
6
Feldmann.
7
Z. Zhang et al, “AAV-Based Dual-Reporter Circuit for Monitoring Cell Signaling in Living Human Cells,”
Journal of Biological Engineering 11, no. 1 (2017), doi:10.1186/s13036-017-0060-9, 18.
8
J. Kowal and M. Tkach, “Biogenesis and Secretion of Exosomes,” Current Opinion in Cell Biology 29 (2014):
116-125, Doi: 10.1016/j.ceb.2014.05.004.
9
M. Rashed et al, “Exosomes: From Garbage Bins to Promising Therapeutic Targets,” International Journal of
Molecular Science 18, no. 3 (2017): 538, Doi: 10.3390ijms18030538.
5

2

that could promote the endocytosis and delivery of their internal content.10 So far, exosomes
have been suggested in a wide range of animal disease models, from cancer,11 to parasitic
infection,12 and even as far as traumatic brain injury.13
1.2.3.1 Exosome Biogenesis
Exosome biogenesis is intimately associated with the endosomal system. Molecules on the
plasma membrane are delivered to early endosomes in endocytic vesicles. Early endosomes
mature into late endosomes where invagination of the membrane causes the formation of
multivesicular bodies (MVBs) containing intraluminal vesicles.14 Finally, fusion of MVBs with
the plasma membrane causes the release of the intraluminal vesicles, now called exosomes.
Another known fate of late endosomes is fusion with the lysosome organelle, a transfer
considered to be unidirectional.15 Soluble molecules within late endosomes, including
intraluminal proteins tagged with ubiquitin, are transported to the lysosome for degradation.16
Hence, molecules potentially secreted in exosomes could otherwise find themselves degraded.
This alternate fate is important to note in our project to observe the extent of colocalization of
our therapeutic exosomes within the lysosomal compartment. Unfortunately, not much is
understood about cellular selection between the fates of late endosomes or MVBs since the
population is thought to be distinctly heterogenous.17

10

S. Kamerkar, and V. LeBleu, “Exosomes Facilitate Therapeutic Targeting of Oncogenic KRAS in Pancreatic
Cancer,” Nature, 2017, 546: 498-503, Doi: 10.1038/nature22341.
11
D. Moris and E. Beal, “Role of Exosomes in Treatment of Hepatocellular Carcinoma,” Surgical Oncology 26, no.
3 (2017): 219-228, doi: 10.1016/j.suronc.2017.04.005.
12
F. Aline et al, “Toxoplasma Gondii Antigen-Pulsed-Dendritic Cell-Derived Exosomes Induce a Protective
Immune Response Against T. Gondii Infection,” Infection and Immunity 72, no. 7 (2004): 4127-37, doi:
10.1128/IAI.72.7.4127-4137.
13
Y. Xiong et al, “Emerging Potential of Exosomes for Treatment of Traumatic Brain Injury,” Neural Regeneration
Research 12, no. 1: 19-22, doi: 10.4103/1673-5374.198966.
14
N. Hessvik and A. Llorente, “Current Knowledge on Exosome Biogenesis and Release,” Cellular and Molecular
Life Sciences 75, no. 2: 193-208, doi:10.1007/s00018-017-2595-9.
15
Hessvik.
16
Hessvik.
17
Hessvik.
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1.2.3.2 Tetraspanin CD63
CD63 is the most abundant of tetraspanin proteins and it is considered a hallmark localizer of
exosomes.18 Tetraspanins consist of both intra and extra-vesicular domains, making them a great
target for modifications.19 Previous studies have shown that both RFP and GFP have been fused
with tetraspanin CD63 and used to track the secretion and uptake of modified exosomes.20
1.2.4 Inflammation Reporter
In order to quantify inflammation in vitro, we utilized a reporter that signaled when the NF-kB
pathway was initiated. Specifically, we used a HEK 293 NF-κB GFP/Luciferase reporter. The
reporter uses a adeno-associated virus (AAV) helper system that contains transcription factor
response elements (TREs) followed by a minimal CMV promoter and GFP-2A-Fireflyluciferase.21 When this dual reporter cell line is in the presence of the inflammatory cytokine
TNFα, Nf-KB is activated and binds to the TREs which leads to the expression of both GFP and
luciferase, which can be quantified and related to cellular levels of inflammation.22

18

Z. Stickney et al, “Development of Exosome Surface Display Technology in Living Human Cells,” Biochemical
and Biophysical Research Communications 472, no. 1 (2016): 53-59, doi: 10.1016/j.bbrc.2016.02.058, 53.
19
Stickney, 53.
20
Stickney, 54.
21
Zhang, 2.
22
Zhang, 5.
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1.3 Drawbacks of Current Technologies
Given rheumatoid arthritis prevalence in the US population, there is a plethora of medications
and therapies currently used for treatment. However, many have significant drawbacks impacting
patient quality of life. In Table 1-1, we outline the mechanism of current treatments, list their
drawbacks, and propose how an exosome-based therapy may circumvent these problems.
Table 1-1: Drawbacks of Current RA Treatments
Treatment

Mechanism of action

Treatment side effects

Exosome-based therapy
solutions

Non-steroid antiinflammatory drugs
(NSAIDs)

Reduces vasodilation by
inhibiting production of
prostaglandins23

Adverse reactions in those
with hepatic and renal
sensitivities24

Exosomes will not block
prostaglandins

Steroids

Mimics anti-inflammatory
properties of naturally
secreted hormones10

Can displace natural
steroid production,
creating dependency10

Localized exosome
therapy will not displace
natural exosomes

Disease modifying
antirheumatic drugs
(DMARDs)

Reduces proinflammatory
cytokines by reducing
folate levels25

Long-term liver toxicity12

Exosomes will not act on
folate levels

Biologics

Inhibits inflammatory
cytokines TNFɑ and IL626

Increased infection risk,
drug becomes ineffective
if doses are skipped27

Antibodies will not
develop against treatment
exosomes

Physical therapy

Maintains muscle strength
and reduces
inflammation28

Accessibility and cost

Not applicable

Joint replacement
surgery

Removes joints too eroded
to function29

Risks of surgery, long
recovery time

Not applicable

23

E. Ricciotti and G. Fitzgerald, “Prostaglandins and Inflammation,” Arteriosclerosis, Thrombosis, and Vascular
Biology 31, no. 5 (2011): 986–1000, doi: 10.1161/atvbaha.110.207449.
24
L. Crofford, “Use of NSAIDs in Treating Patients with Arthritis,” Arthritis Research & Therapy 15 (2013).
25
M. Nurmohamed and B. Dijkmans, “Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying
Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis,” Drugs 65, no. 5 (2005): 661-694, doi:
10.2165/00003495-200565050-0006.
26
J. Singh et al, “Adverse Effects of Biologics: A Network Meta-Analysis and Cochrane Overview,” Cochrane
Database of Systematic Reviews 2.
27
L. Putte et al, “Adalimumab,” TNF-Inhibition in the Treatment of Rheumatoid Arthritis, 2004, 71-88, doi:
10.3109/9780203624388-5.
28
V. Kavuncu and D. Evcik, “Physiotherapy in Rheumatoid Arthritis,” Medscape General Medicine 6, no. 2, doi:
10.3109/9780203624388-5.
29
“Joint Replacement Surgery,” National Institute of Arthritis and Musculoskeletal and Skin Diseases, October 4,
2017, Accessed June 11, 2018. https://www.niams.nih.gov/health-topics/joint-replacement-surgery.
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1.4 Project Goals and Constraints
Our project goal is to take the specificity of biologics one step further using naturally secreted
nanoparticles. However, it is important to note that our project is only one step in a long line of
research necessary to safely implement a novel RA therapeutic. For instance, we cannot measure
general clinical outcomes such as liver toxicity due to institutional limitations on animal testing,
nor do we have the means to perform purity analysis. Our project, furthermore, is far from allencompassing; we do not aim to replace physical therapy or joint replacement surgery with our
exosomal therapy, as they are required in extreme circumstances. Instead, we evaluated the
efficacy of our exosomes in a cell culture model, extrapolating existing literature on exosomal
treatment to make clinical predictions when appropriate. For this reason, we propose a proof of
concept for reducing inflammation in vitro.
Our project is nominally divided into three phases or goals. The first goal of our project was to
create a stable cell line that produced engineered exosomes. The second goal involved
confirmation of the desired modifications via fluorescence imaging. Following successful
production of our therapeutic exosomes, we tested their efficacy in a quantitative assay in the
third and final goal.
1.4.2 Phase 1: Production
In phase 1, we focused on creating a stable cell line that produced engineered exosomes capable
of preventing inflammation. Next, we harvested these exosomes and store them for phases 2 and
3 of our project.
1.4.3 Phase 2: Characterization
In phase 2, we aimed to confirm that we had made the desired modifications to our stable cell
lines. We followed the biogenesis of exosomes using various markers to ensure that our TNFR
had been added to the surface of the exosomes.

6

1.4.4 Phase 3: Testing
In phase 3, we utilized our reporter cell line to determine the effect of our engineered exosomes
on the inflammatory response of human cells in vitro.

1.5 Back-Up Plan
Despite careful aseptic technique, research with mammalian cell lines is notably susceptible to
unforeseen contamination in the form of bacteria or fungi. In order to prevent contamination that
could jeopardize the timeline of our project, we continually made frozen copies of our stable cell
lines to store at -80C. Although this procedure was critically important to staying ahead of
deadlines, it is hardly unique to our project. Project specific back-up plans include the option to
engineer TNFR onto a different scaffold, such as VSVG or RD114, if our CD63-TNFR-GFP
exosomes are not successful in significantly reducing inflammation. Secondly, we could refocus
our attention on other inflammatory cytokines implicated in the RA transduction cascade like IL1 and IL-6.

1.6 Significance
If our proposed therapy is successful in preventing inflammation in-vitro, it could be one of the
first exosome-based therapies to be tested in animals and clinical trials. Due to the natural
stability of exosomes in the body and the fact that they do not initiate an adverse immune
response, our proposed therapy has the potential to be as effective as DMARDs or biologics
without the significant drawbacks of those classes of drugs. The technology utilized by our
proposed exosome therapy could also be applied to a number of other therapeutic uses, such as
gene therapies, immunotherapies, and targeted drug delivery.

1.7 Team Management
As a team, we have shared equal responsibility maintaining our cell lines, designing and
performing experiments, and analyzing data. Dr. Lu provides guidance through regular
correspondence and weekly meetings.

7

1.8 Budget
See Table 1-2 below for our project budget.
Table 1-2: Project Budget
Flasks and Plates

$250

Fetal Bovine Serum

$250

Culture Media

$500

TNFα

$210

Serum Free Media

$120

Luciferase Assay

$250

Endosomal Stains

$500

Transfection Reagent

$1000

Total Cost

$3080
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1.9 Timeline
Our project timeline is outlined below in Table 1-3.
Table 1-3: Project Timeline
Fall Quarter

Winter Quarter

Spring Quarter

X

Establish Cell Lines

X

Maintain Cell Lines

X

X

Characterize and Image

X

X

Exosomes
Track exosomes through

X

endosome pathway
Evaluate Dose Response

X

X

Write Thesis

X

X

Present Results

X
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2. Creating Stable Cell Lines to Produce Therapeutic
Exosomes
2.1 Design Description
In order to produce and collect modified exosomes efficiently, we decided to create two stable
cell lines. Our treatment stable cell line utilizes CD63 tetraspanin to anchor a TNFR along with
GFP to the surface of exosomes. Based on prior experimentation, we anticipated that this TNFR
on the surface of the exosomes would soak up excess TNFα and thereby prevent the initiation of
inflammation in cells. We also created a control stable cell line for experimentation purposes,
replacing the TNFR with RFP. Both cell lines utilized HEK 293 cells transfected with our
desired DNA constructs and a puromycin resistance gene in order to select for our transfected
cells.

2.2 Key Constraints
To prevent cells without our desired construct from growing, we grew our stable cell lines in
media containing the antibiotic puromycin for a period of 10 weeks. Antibiotics can be harsh on
cells, so finding the correct dose that would kill cells without our desired modifications but
would also allow the resistant cells to thrive can be difficult. One must consistently monitor the
cells to ensure that only the cells without the desired modifications (the cells that do no fluoresce
green) are killed off.

2.3 Expected Results
We expected to see GFP expressed in all of our HEK 293 CD63-TNFR-GFP cells and both GFP
and RFP expressed in all of our HEK 293 CD63-RFP-GFP cells after the 10 week treatment with
puromycin. This period of treatment should have been sufficient for killing off any untransfected
cells. Final results are shown in section 6.1.
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2.4 Materials and Methods
The following table (Table 2-1) contains the necessary materials to create our stable cell lines.
Table 2-1: Materials for Creating Stable Cell Lines
Material

Company/Brand

Model #

Passaging Mammalian Cells
Materials (See Appendix)
HEK 293 cells

N/A

HEK 293 CD63-RFP-GFP Stable
Cell Line
DMEM + 10% FBS + PS media
ThermoFisher Scientific

A1113802

FuGene HD Transfection Reagent

Promega

E231A

Microcentrifuge tubes

Sigma-Aldrich/ Eppendorf SafeLock

T9661

ThermoFisher Scientific

31985062

Puromycin

Opti-MEM Reduced Serum Media

DNA Plasmids (CD63-TNFR-GFP

Genscript

and CD63-RFP-GFP)

Methods
Day 1
1. Use protocol for passaging mammalian cells onto a 60mm x 15mm dish and incubate at 37°C
for 24 hours.
Day 2
2. After 24 hours, combine reduced-serum media (Opti-MEM) and FuGene HD Transfection
Reagent at a ratio of 2µg of DNA per 4µl of transfection reagent.
3. Incubate at room temperature for 5 minutes.
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4. Carefully add 1.5µg/mL of DNA plasmid into the reduced-serum media (Opti-MEM) and
transfection reagent mixture.
5. Incubate the mixture at room temperature for 20-30 minutes.
6. Carefully add the mixture to the cell culture dish.
7. Incubate the dish at 37°C for 24 hours.
Days 4-70
8. Add 5µg/ml of puromycin to 50 mL of DMEM + 10% FBS + PS media and repeat as needed.
9. Use protocol for passaging mammalian cells and plate the cells in the media created in step 8.
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3. Image Characterization of Therapeutic Exosomes
3.1 Design Description
After creating our treatment stable cell line (HEK 293 CD63-TNFR-GFP), we wanted to ensure
that the exosomes it produced had been successfully modified. To do this, we decided to track
the exosomes at each stage of their biogenesis. As discussed in the introduction, exosomes
originate from the intraluminal budding of multivesicular endosomes. Therefore, we decided to
utilize RFP stains for both early and late stage endosomes to visualize if our modified exosomes
followed this path of biogenesis. We also utilized a lysosome tracker, as late stage endosomes
can be digested by lysosomes. Finally, we performed a co-transfection of our stable cell line with
an exosome localizer and RFP to ensure that our TNFR-GFP construct had successfully localized
onto the surface of exosomes. All of the stains and the co-transfection were performed in a 4chamber glass bottom plate, as shown in Figure 3.1.1.

Figure 3.1.1: Schematic of characterizing stains in a four-chamber plate.

3.2 Key Constraints
The key constraints for this portion of the project centered on the transfection and staining
efficiency of our reagents. Some factors affecting this are cell confluency, reagent age, and
seeding uniformity. Cell confluency and seeding uniformity can also affect image quality.
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3.3 Expected Results
We expected to see the GFP on our modified exosomes colocalize with the both the early and
late endosome stains, as well as the RFP exosome localizer. When overlaying images taken with
RFP and GFP filters, we expected to see the two colors overlap and appear yellow. Final results
are shown in section 6.2.
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3.4 Materials and Methods
The following tables (Table 3-1) includes the necessary materials to perform the characterization
experiments outlined in section 3.1.
Table 3-1: Materials for Characterization
Material

Company/Brand

Model #

Created in lab

N/A

ThermoFisher/CellLight

C10587

ThermoFisher/CellLight

C10589

ThermoFisher/Invitrogen

L7528

ThermoFisher Scientific

31985062

In Vitro Scientific

D35C4-20-1.5-N

Created in lab

N/A

System Biosciences/XPack

XPAK531PA-1

Matsunami Glass

D35-14-1.5-U

Passaging Mammalian Cells
Materials (See Appendix)
CD63-TNFR-GFP stable cell line
Early Endosomes-RFP, BacMam
2.0

Late Endosomes-RFP, BacMam 2.0

LysoTracker Red DND-99

Opti-MEM Reduced Serum Media

4-chamber 35 mm glass-bottom
plate

1 g/L polyethylenimine (PEI)
transfection reagent

CMV-XP-RFP-EF1α expression
vector

35 mm glass-bottom plate
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Methods
Day 1
1. Seed cells for endosome imaging
1.1. Use protocol for passaging mammalian cells to seed HEK 293 CD63-TNFR-GFP
cells into all chambers of the 4-chamber 35 mm glass bottom plate at a density of 2x105
cells/ml with DMEM + FBS + PS media.
1.1.1. Each chamber of the glass-bottom plate contains 500 µL; add cells one
chamber at a time to ensure equal cell density.
1.2. Designate the 4 chambers as early endosome, late endosome, lysosome, and no
transfection.
1.3. Incubate at 37°C for 24 hours.
2. Seed cells for exosome imaging
2.1. Use protocol for passaging mammalian cells to seed HEK 293 CD63-TNFR-GFP
cells into five 35 mm glass bottom plates at a density of 2x105 cells/ml with DMEM +
FBS + PS media.
2.2. Designate 4 plates to be transfected with CMV-XP-RFP-EF1α DNA and one plate to
remain untransfected for control.
2.3. Incubate at 37°C for 24 hours.
Day 2
3. Transfect cells with late and early endosome markers
3.1. Estimate the number of cells in each chamber via light microscopy.
3.2. Add 2 µL of early or late endosome mix per 45,000 cells to respective chambers.
3.3. Incubate at 37°C for 16-24 hours.
4. Transfect cells with exosome marker (for each transfected dish)
4.1. Aliquot 100 µL of opti-MEM media.
4.2. Since each dish requires about 2µg of CMV-XP-RFP-EF1α DNA and 5 µL of 1 g/L
PEI is required to encapsulate 1 µg of DNA, add 10 µL of PEI to opti-MEM.
4.3. Allow PEI and opti-MEM mixture to sit at room temperature for 5 minutes.
4.4. Add 2µg of CMV-XP-RFP-EF1α DNA to mixture and allow to sit at room
temperature for 20 minutes.
4.5. Add 100 µL of mixture to each transfected dish.
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4.6. Incubate dishes at 37°C for 24 hours.
Day 3
5. Stain lysosomes and image all cells
5.1. Dilute stock LysoTracker Red DND-99 to a concentration of 50-75nM in cell culture
media.
5.2 Add 1µL of lysosome stain to designated chamber.
5.3 Incubate at 37°C for 45 minutes.
6. Capture phase contrast, RFP, and GFP images of each transfection at 40x
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4. Testing Efficacy of Therapeutic Exosomes:
Direct Treatment
4.1 Design Description
After creating our stable cell line, we wanted to test the efficacy of our CD63-TNFR-GFP
exosomes. To do this, we added TNFα to half of the wells of our HEK 293 Nfkb dual reporter
cells to simulate inflammation as well as varying concentrations (0.5mg/ml, 0.1mg/ml, and 0
mg/ml) of our CD63-TNFR-GFP treatment exosomes or our CD63-RFP-GFP control exosomes.
Each experimental condition was run in triplicate. We then utilized a luciferase assay to
determine whether our treatment exosomes had successfully inhibited TNFα initiated
inflammation in vitro.

4.2 Key Constraints
The key constraints for this portion of the project centered on the response sensitivity and
volume of the HEK 293 Nfkb dual reporter cells. These constraints were controlled by reporter
system expression and the number of seeded cells, respectively. A second constraint was the
degradation of the luciferase assay reagent (LAR). LAR is time and light sensitive, therefore our
results also depended on this substrate’s quality.

4.3 Expected Results
We expected to see a statistically significant reduction in luciferase fluorescence--corresponding
to a reduction in inflammation--only when we add CD63-TNFR-GFP exosomes. We also
expected this response to be dependent on the exosome concentration. Final results are shown in
section 6.3.

18

4.4 Materials and Methods
The following table (Table 4-1) includes the materials required to perform the direct treatment
efficacy assay.
Table 4-1: Materials for Efficacy of Design Experiment: Direct Treatment
Material

Company/Brand

Model #

DMEM + 10% FBS + PS media

Created in lab

N/A

Serum-Free Medium without LGlutamine

BioWhittaker/ UltraCULTURE

12-725F

96 well plate, clear bottom

Greiner Bio-one/Cellstar

655180

Recombinant Human TNFα Protein

R&D Systems

210-TA-020

Passaging Mammalian Cells
Materials (See Appendix)

Materials for Luciferase Assay (See
Appendix A4)

Methods
Day 1
1. Seed cells
1.1 Use protocol for passaging mammalian cells to seed HEK 293 NfKB reporter cells
into 36 wells of the 96-well plate at a density of 1x105 cells/ml with DMEM + FBS + PS
media.
1.2 Incubate the plate at 37°C for 24 hours.
Day 2
2. Treat cells with recombinant human TNFα and exosomes.
2.1 Add recombinant human TNFα protein to serum-free media to create a stock
concentration of 100 ng/mL TNFα.
2.2. Create stock concentrations of CD63-TNFR-GFP exosomes of 0, 0.1, and
0.5mg/mL in serum-free media.
2.3. Create stock concentrations of CD63-RFP-GFP exosomes of 0, 0.1, and
0.5mg/mL in serum-free media.
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2.4. Add stock TNFα protein solution to appropriate exosome solutions to create a
working concentration of 1 ng/mL TNFα.
2.5 Tilt the plate and carefully aspirate the media off each well.
2.6. Carefully add 100µL of the various serum-free media conditions to each well.
2.7. Incubate at 37°C for 24 hours.
Day 3
3. Perform luciferase assay (See Appendix A4).
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5. Testing Efficacy of Therapeutic Exosomes: Coculture
5.1 Design Description
In this experimental model, we wanted to determine the effect our CD63-TNFR-GFP exosomes
would have in reducing inflammation in coculture with the HEK 293 Nfkb dual reporter cells.
The cells were seeded in a 3:1 ratio of exosome producing cells to reporter cells. This allowed
for a sufficient number of modified exosomes to be produced and released from the stable cell
lines. HEK 293 CD63-RFP-GFP cells were used as control and plain HEK cells were used as
background. Six wells of each coculture condition were plated and TNFα was added to half of
the wells. A luciferase assay was then performed to determine the extent to which our exosomes
inhibited TNFα.

5.2 Key Constraints
The biggest constraint with this experimental model was that we did not know how many
exosomes were produced by the cells in coculture with the reporter cell line. Therefore, we were
unable to determine an effective dosage of CD63-TNFR-GFP exosomes using this model.

5.3 Expected Results
We expected that the exosomes secreted by our stable cell line in coculture with the reporter cell
line would effectively decrease levels of TNFα. However, since the overall concentration of
treatment exosomes was likely lower in this model than in the direct treatment model, the effect
was not as pronounced. Final results are shown in section 6.3.
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5.4 Materials and Methods
Table 5-1 includes the materials necessary to perform the coculture efficacy assay.
Table 5-1 Materials for Efficacy of Design Experiment: Coculture
Material

Company/Brand

Model #

DMEM + 10% FBS + PS media

Created in lab

N/A

Recombinant Human TNFα Protein

R&D Systems

210-TA-020

Serum-Free Medium without LGlutamine

BioWhittaker/ UltraCULTURE

12-725F

Greiner Bio-one/Cellstar

655180

Passaging Mammalian Cells
Materials (See Appendix)

96 well plate, clear bottom
Materials for Luciferase Assay (See
Appendix A4)

N/A

Methods
Day 1
1. Seed cells
1.1 Create stock concentrations of exosome producing cells (HEK 293, HEK 293 CD63RFP-GFP, HEK 293 CD63-TNFR-GFP) and reporter cell line HEK 293-NfKB Dual
Reporter in suspension at 1x105 cells/ml.
1.2 Plate 100 ul per well comprised of 75 ul of exosome producing suspension and 25 ul
of reporter cell suspension across the following groups: HEK 293 vs Reporter, RFP-GFP
vs Reporter, TNFR-GFP vs Reporter.
1.3 Incubate 48 hours
Day 3
2. Treat half the groups with Recombinant Human TNFα Protein at 1 ng/ml. Incubate 24 hours at
37°C.
Day 4
3. Perform Luciferase Assay (See Appendix A4).
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6. Results
6.1 Creation of Stable Cell Lines
We succeeded in creating a stable cell line that produces our modified, decoy exosomes, as well
as a second stable cell line for experimental control. Figures 6.1.1 and 6.1.2 show the expression
of our desired DNA constructs in HEK 293 cells. The localization of fluorescence to small dots
outside the cells’ nuclei shows that our constructs have been integrated into the membranes of
exosomes.

Figure 6.1.1: HEK 293 CD63-TNFR-GFP stable cell line. Modified exosomes represented by GFP.
Images taken at 40x.

Figure 6.1.2: HEK 293 CD63-RFP-GFP stable cell line for experimental control. Images taken at 40x.
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6.2 Characterization
Imaging confirmed that our desired modifications had been made to the surface of exosomes
produced by the HEK 293 CD63-TNFR-GFP stable cell line. Images show colocalization of
exosomes with both early and late stage endosomes (Figure 6.2.1 A and B), which demonstrates
that our modifications are following the path of exosome biogenesis. As discussed in 1.2.3.1,
exosomes may follow an alternate path and reside within lysosomes. Imaging shows that our
modified exosomes also colocalize with lysosomes (Figure 6.2.1 C). An exosome-specific
marker (XPACK-RFP) also colocalizes with our CD63-TNFR-GFP exosomes (Figure 6.2.2).
Colocalization of each of the RFP markers with GFP is represented as yellow in the overlaid
images.

Figure 6.2.1: HEK 293 CD63-TNFR-GFP cells with A: Early Endosome RFP Marker, B: Late Endosome RFP
Marker, and C: Lysosome RFP Marker. All images taken at 40x.

Figure 6.2.2: HEK 293 CD63-TNFR-GFP cells with XPACK-RFP, an exosome localizer. Images taken at 40x.
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6.3 Efficacy
The presence of our treatment exosomes was successful in reducing levels of TNFα in both the
coculture and direct treatment models. Inflammation was quantified in both models using the
HEK 293 Nfkb dual reporter cell line. A decrease in levels of TNFα corresponds to a decrease in
luminescence detected during our assay.
As shown in Figure 6.3.1, our exosomes produced in coculture with the reporter cell line were
able to significantly reduce (p=0.036) the levels of TNFα compared to the experimental
condition with natural, HEK exosomes only.

Figure 6.3.1: Efficacy of exosome producing stable cell lines in coculture with HEK 293 Nfkb dual reporter cells.
N=9 from three separate trials. Error bars represent standard error of the mean.
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The direct treatment model also showed a significant decrease in TNFα levels with the addition
of 0.5mg/ml of CD63-TNFR-GFP exosomes (Figure 6.3.2).

Figure 6.3.2: Efficacy of 0.5mg/ml exosomes added directly to HEK 293 Nfkb dual reporter cells. N=9 from three
separate trials. Error bars represent standard error of the mean.
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7. Discussion and Conclusion
Our results show that the concept of an effective, exosomal decoy treatment for inflammation is
possible. In the production phase of our project, we find that our stable cell lines expresses GFP
and RFP, as expected. In the verification phase, we confirm that the particles our cell lines
produce are exosomes due to colocalization features with other cell compartments. Most
importantly, we prove that both models of efficacy experiments show a significant decrease in
inflammation due to the presence of the exosomes we created. This fact, combined with the
penetrative capacity known of exosomes and their longer biological half-life, indicates a solid
footing into further exosome research for RA. If our treatment is proven to work in animal and
human models, it has the potential to be one of the first exosomal treatments. Future work, such
as purity testing, high-throughput production design, and observation of cytotoxic and organ
system effects would be the best way to continue this project, but would require outside help and
better equipment.
We hope that our project will trigger more research into exosomal decoy therapies for other
human diseases. Besides RA, exosomes have a promising ability to deliver enzymes to the lumen
of the lysosomes for patients with a wide-variety of lysosomal storage diseases such as
Gaucher’s or Tay Sachs.
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8. Engineering Standards and Realistic Constraints
8.1 Social impact
By utilizing exosomes for our treatment, we believe that the therapeutic effects of our anchored
TNF receptor will be superior to treatments utilizing soluble TNFR. This would primarily be due
to exosomes’ long half-life in the body, as well as their ability to deeply penetrate inflamed
tissues. This targeted therapeutic will also be less wasteful than current soluble TNFR
treatments; soluble TNFR will degrade much faster than TNFR anchored to an exosomal
membrane. Hopefully, this will result in the patient requiring fewer injections, which will
improve their quality of life by decreasing the number of times they have to visit a doctor.

8.2 Health and Safety
Any medical therapy must undergo rigorous testing before being administered to humans. Our
project is focused on manufacturing, characterizing, and testing therapeutic exosomes in vitro,
and can therefore be classified as pre-clinical. The first step to ensuring the safety of our
therapeutic would be to perform a toxicity assay in a mammalian cell culture model.
Unfortunately, our lab does not have the resources to move forward with the next steps in safety
testing. However, if our therapeutic were to proceed to clinical trials, it would be tested in
animals before beginning four phases of human trials.

8.3 Manufacturability
A major issue encountered in our design project was the efficient and reliable production of
engineered exosomes at a rate that would warrant its use as a therapeutic. Previous to our work
on the project, the procurement of therapeutic exosomes required transient transfection of our
construct immediately prior to each harvest being performed. Sustained gene expression
guaranteed by stable cell lines allowed us to more quickly and reliably harvest therapeutic
exosomes and cut down the cost incurred through prodigal use of transfection reagents.
Further improvements to exosome harvest and purification could allow more efficient
manufacturability in the future. Cellular exosome yield could be drastically heightened with the
introduction of better, more suitable conditions using a controlled bioreactor. Modulation of pH,
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temperature, or agitation may change the ability of our cells to produce exosomes. Additionally,
the efficacy experiments indicated that a high concentration of exosomes induced a modest
reduction in the inflammation pathway response. However, we have reason to believe that the
concentration indicated by the nanodrop lite may erroneously register the additive effect of
artifacts and thus display false readings. A better protein expression system to gauge the purity
and true concentration of our purified exosomes is needed to achieve desired manufacturability.

8.4 Economic
As we noted in our introduction, novel biologics that work via inhibition of inflammatory
cytokines IL-6 and TNFα have the potential to induce antagonistic antibody production or allow
the reactivation of latent infections such as tuberculosis. These could lead to far more expensive
medical costs. Furthermore, effective use of these therapies requires regular and expensive
treatment. Our exosomes have the potential to reduce cost by limiting the number of times a
patient must return for treatment. Exosomes boast a longer half-life in the body, and do not
threaten to evoke deleterious immune responses that pile up the medical bills.

8.5 Ethical implications
We chose to work on this project because we believed that this novel treatment had the potential
to impact the millions of people suffering from a disease as debilitating as rheumatoid arthritis. A
chronic illness severely limits patients’ autonomy and can prevent them from living a satisfying
life. We hope that a therapy that aids symptom management for RA will promote patients’
autonomy. From a utilitarian point of view, developing a new treatment that will be less
expensive for patients, ease their pain, and require them to visit the doctor less often is doing
moral good.
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Appendix
A1: Making Media: DMEM + 10% FBS + PS
Table A1-1: Materials for Making Media
Material

Company/Brand

Model #

Dulbecco’s Modified Eagle
Medium with L-Glutamine
(DMEM)

Thermo Fisher Scientific/Gibco

11965092

Fetal Bovine Serum (FBS)

Thermo Fisher Scientific/Gibco

10438034

Penicillin-Streptomycin (PS)

Thermo Fisher Scientific/Gibco

15140122

1. Add 50 mL of FBS into a 500ml bottle of DMEM with L-Glutamine.
2. Add 5 mL of PS to the combined FBS and DMEM.
3. Mix thoroughly.
4. Store at 4°C until needed.

A2: Passaging Cells
Table A2-1: Materials for Passaging Cells
Material

Company/Brand

Model #

DMEM + 10% FBS + PS media

N/A

N/A

Phosphate Buffered Saline
pH 7.4 (PBS)

Thermo Fisher Scientific

AM9625

Trypsin 0.25% with phenol red

Thermo Fisher Scientific

15050065

15 mL conical-bottom centrifuge
tubes

VWR

89039-666

1. Aspirate depleted media
2. Wash with 3 mL of PBS. Pipet gently into side of plate.
3. Aspirate PBS.
4. Add 1.5 mL of trypsin to plate.
5. Incubate at 37°C for 2 minutes.
6. Deactivate trypsin with 4.5 mL of DMEM + 10% FBS + PS media.
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7. Collect media in 15 mL centrifuge tube, spin at 1500 RPM for 5 minutes.
8. Aspirate off supernatant.
9. Resuspend the pellet in DMEM + 10% FBS + PS media.
10. Plate at desired density.

A3: Harvesting Exosomes
Table A3-1: Materials for Exosome Harvest
Material

Company/Brand

Model #

Dish 145mmx20mm

Sigma-Aldrich/ Greiner

639160

Serum-Free Medium without LGlutamine

BioWhittaker/ UltraCULTURE

12-725F

50 mL conical-bottom
centrifuge tubes

VWR

89039-658

Syringe, 30 mL

BD Biosciences/ BD Luer-Lok

Sterile hydrophobic filter, 0.2
micron

BD Biosciences/ BD Influx

645270

Exosome precipitation solution

SBI/ ExoQuick

EXOQ5A-1

Phosphate-Buffered Saline pH 7.4
(PBS)

Thermo Fisher Scientific

AM9625

Cryogenic vials

Sigma-Aldrich/ Nalgene

V4757

Passaging Mammalian Cells
Materials (See Appendix A1)

Day 1
1. Seed Cells
1.1. Using a passaging mammalian cells protocol (Appendix A2-B), seed stable cell lines
onto 145mmx20mm dishes at 40-60% confluency (2-3x105 cells/mL) with DMEM +
10% FBS + PS media.
1.2. Incubate at 37°C for 24 hours or until 70-80% confluent.
Day 2:
2. Change media
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2.1. Aspirate off DMEM + 10% FBS + PS media and replace with equal volume of
serum-free media without L-glutamine.
2.2. Incubate at 37°C for 48 hours.
Day 4:
4. Exosome Harvest Part I
4.1. Collect the serum-free medium into a 50 mL centrifuge tube.
4.2. Centrifuge the 50 mL centrifuge tube at 1500xg for 10 minutes.
4.3. Filter the supernatant through a 0.2-micron filter with a sterile 30 mL syringe into a
new 50 mL centrifuge tube.
4.4. Add 1⁄4 of the supernatant volume of exosome precipitation solution.
4.5. Incubate at 4°C for 24 hours.
Day 5:
5. Exosome Harvest Part II
5.1. Centrifuge the 50 mL centrifuge tube from Day 4 at 3000xg for 45-90 minutes.
5.2. Carefully aspirate off the supernatant, taking care to not disturb the pellet on the side
of conical tube.
5.3. Resuspend the pellet in 50 µl-100 µl of PBS.
5.4. Store in a cryogenic vial at -80°C until needed.

A4: Luciferase Assay
Table A4-1: Materials for Luciferase Assay
Material

Company/Brand

Model #

Plate Reader

BMG Lab Tech/LUMIstar Omega

S/N 415-1717

Luciferase Assay Buffer (LAB)

Promega

E1501

Luciferase Assay Substrate (LAS)

Promega

E1501

Passive Lysis Buffer (PLB)

Promega

E1501

1. Prepare Luciferase Assay Reagent (LAR) by combining 10mL of LAB with an entire vial of
LAS. Pipette up and down to mix.
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2. Dilute the Passive Lysis Buffer (PLB) by combining stock with 4x volume of DI water.
3. Add 20µL of diluted lysis buffer to each well.
4. Mix with gentle rotations for 10 minutes.
5. Turn on computer and plate reader.
6. Set up plate reader to measure luminescence with a read time of 10 seconds and set the
attenuation to none.
7. Quickly add 100µL of LAR to each well, ensuring that the order in which you add the LAR is
the order in which the plate reader will read the wells.
8. Immediately run the plate in the plate reader.
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